Connect Sign In
2012166
Dihydropyrimidine Dehydrogenase (DPYD)
DPYD
Ordering Recommendation
Predicts risk of dose-related toxicity to 5-FU therapy.
New York DOH Approval Status
This test is New York state approved.
Specimen Required
Patient Preparation
Collect
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL)
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Plasma or serum. Heparinized specimens. Frozen specimens in glass collection tubes.
Remarks
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month.
Methodology
Polymerase Chain Reaction (PCR)/Fluorescence Monitoring
Performed
Varies
Reported
5-10 days
Reference Interval
Interpretive Data
Refer to report.
Compliance Category
Laboratory Developed Test (LDT)
Note
Hotline History
Hotline History
Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
N/A
CPT Codes
81232
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2012167 | DPYD Specimen | 31208-2 |
| 2013096 | DPYD Genotype | 45284-7 |
| 2013097 | DPYD Phenotype | 79719-1 |
| 3016868 | EER Dihydropyrimidine Dehydrogenase | 11526-1 |
| 3017865 | DPYD Interpretation | 79719-1 |
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
- Fegafur
- Xeloda
- Capecitabine
- DPYD genotyping
- Dihydropyrimidine
- 5FU drug toxicity
- DPD
- DPYD
- Uftoral
Dihydropyrimidine Dehydrogenase (DPYD)
